<p>Tiziana Life Sciences Ltd（納斯達克：TLSA - 獲取免費報告）週三的股價上漲了 0.7%。該股票最高交易價為 1.4099 美元，最後交易價為 1.40 美元。當天中午交易中，共交易了 76,328 股，較平均交易量 195,954 股下降了 61%。該股票此前收盤價為 1.39 美元。</p>
<p>獲取 <strong>Tiziana Life Sciences</strong> 的提醒：</p>
<h2>分析師評級變動</h2>
<p>另外，Weiss Ratings 在 1 月 21 日的報告中重新發布了對 Tiziana Life Sciences 股票的 “賣出（d-）” 評級。一位研究分析師對該股票給予了賣出評級。根據 MarketBeat.com 的數據，該公司的平均評級目前為 “賣出”。</p>
<p><strong>獲取我們最新的 TLSA 股票分析</strong></p>
<h2>Tiziana Life Sciences 股票表現</h2>
<p>該公司的 50 日移動平均線為 1.51 美元，200 日移動平均線為 1.76 美元。</p>
<h2>機構投資者對 Tiziana Life Sciences 的看法</h2>
<p>一些機構投資者和對沖基金最近對 TLSA 的持倉進行了調整。Rachor Investment Advisory Services LLC 在第四季度收購了 Tiziana Life Sciences 的新股份，價值約 25,000 美元。Cubist Systematic Strategies LLC 在第一季度收購了 Tiziana Life Sciences 的新股份，價值約 25,000 美元。Marshall Wace LLP 在第二季度收購了 Tiziana Life Sciences 的新股份，價值約 39,000 美元。HRT Financial LP 在第四季度購買了 Tiziana Life Sciences 的新頭寸，價值約 36,000 美元。最後，ARS Investment Partners LLC 在第三季度收購了 Tiziana Life Sciences 的新頭寸，價值 66,000 美元。</p>
<h2>關於 Tiziana Life Sciences</h2>
<p>（獲取免費報告）</p>
<p>Tiziana Life Sciences plc（納斯達克：TLSA）是一家臨牀階段的生物技術公司，專注於在腫瘤學、免疫學和傳染病領域開發新型治療藥物。公司總部位於倫敦，在馬薩諸塞州劍橋市設有研發機構，致力於推進小分子抑制劑和單克隆抗體候選藥物的研發，旨在調節免疫通路和靶向腫瘤生長。</p>
<p>該公司的主要小分子項目 milciclib 是一種口服細胞週期依賴性激酶抑制劑，目前正在進行針對肝細胞癌和某些神經內分泌腫瘤的二期臨牀試驗。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Tiziana Life Sciences</li>
<li>有 500 美元？投資於埃隆的人工智能大師計劃</li>
<li>你的銀行賬户不再安全</li>
<li>白銀支付 20% 的股息，外加 68% 的股價上漲</li>
<li>美聯儲剛剛遭遇重創——接下來會發生什麼</li>
<li>這隻 15 美元的股票可能會成為 2026 年的第一隻股票</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元於 Tiziana Life Sciences 嗎？</h2>
<p>在考慮 Tiziana Life Sciences 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Tiziana Life Sciences 並不在名單上。</p>
<p>雖然 Tiziana Life Sciences 目前在分析師中被評為賣出，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

醫療業 ETF - Vanguard

醫療業 ETF - SPDR

納斯達克生物科技指數 ETF - iShares Nasdaq

<p>Tiziana Life Sciences（納斯達克代碼：TLSA）股價在交易中上漲 0.7%，至 1.40 美元，成交量較平均水平下降 61%。分析師對該股票給予 “賣出” 評級，Weiss Ratings 重申了 “賣出（d-）” 評級。機構投資者最近已在該公司中獲得股份，該公司專注於開發腫瘤學和傳染病的治療藥物。儘管股價略有上漲，但並不受到頂級分析師的青睞，他們推薦其他股票</p>

<p>Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report)'s share price shot up 0.7% during trading on Wednesday . The stock traded as high as $1.4099 and last traded at $1.40. 76,328 shares were traded during mid-day trading, a decline of 61% from the average session volume of 195,954 shares. The stock had previously closed at $1.39.</p>
<div class="lb-trans"><p>Tiziana Life Sciences Ltd（納斯達克：TLSA - 獲取免費報告）週三的股價上漲了 0.7%。該股票最高交易價為 1.4099 美元，最後交易價為 1.40 美元。當天中午交易中，共交易了 76,328 股，較平均交易量 195,954 股下降了 61%。該股票此前收盤價為 1.39 美元。</p>
</div><p>Get <strong>Tiziana Life Sciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Tiziana Life Sciences</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>Separately, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Tiziana Life Sciences in a report on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>另外，Weiss Ratings 在 1 月 21 日的報告中重新發布了對 Tiziana Life Sciences 股票的 “賣出（d-）” 評級。一位研究分析師對該股票給予了賣出評級。根據 MarketBeat.com 的數據，該公司的平均評級目前為 “賣出”。</p>
</div><p><strong>Get Our Latest Stock Analysis on TLSA</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 TLSA 股票分析</strong></p>
</div><h2>Tiziana Life Sciences Stock Performance</h2>
<div class="lb-trans"><h2>Tiziana Life Sciences 股票表現</h2>
</div><p>The firm's 50-day moving average is $1.51 and its two-hundred day moving average is $1.76.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均線為 1.51 美元，200 日移動平均線為 1.76 美元。</p>
</div><h2>Institutional Investors Weigh In On Tiziana Life Sciences</h2>
<div class="lb-trans"><h2>機構投資者對 Tiziana Life Sciences 的看法</h2>
</div><p>A number of institutional investors and hedge funds have recently made changes to their positions in TLSA. Rachor Investment Advisory Services LLC acquired a new stake in shares of Tiziana Life Sciences during the fourth quarter worth about $25,000. Cubist Systematic Strategies LLC acquired a new stake in Tiziana Life Sciences during the 1st quarter worth approximately $25,000. Marshall Wace LLP acquired a new stake in Tiziana Life Sciences during the 2nd quarter worth approximately $39,000. HRT Financial LP purchased a new position in Tiziana Life Sciences in the 4th quarter valued at approximately $36,000. Finally, ARS Investment Partners LLC acquired a new position in shares of Tiziana Life Sciences in the third quarter worth $66,000.</p>
<div class="lb-trans"><p>一些機構投資者和對沖基金最近對 TLSA 的持倉進行了調整。Rachor Investment Advisory Services LLC 在第四季度收購了 Tiziana Life Sciences 的新股份，價值約 25,000 美元。Cubist Systematic Strategies LLC 在第一季度收購了 Tiziana Life Sciences 的新股份，價值約 25,000 美元。Marshall Wace LLP 在第二季度收購了 Tiziana Life Sciences 的新股份，價值約 39,000 美元。HRT Financial LP 在第四季度購買了 Tiziana Life Sciences 的新頭寸，價值約 36,000 美元。最後，ARS Investment Partners LLC 在第三季度收購了 Tiziana Life Sciences 的新頭寸，價值 66,000 美元。</p>
</div><h2>About Tiziana Life Sciences</h2>
<div class="lb-trans"><h2>關於 Tiziana Life Sciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Tiziana Life Sciences plc NASDAQ: TLSA is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.</p>
<div class="lb-trans"><p>Tiziana Life Sciences plc（納斯達克：TLSA）是一家臨牀階段的生物技術公司，專注於在腫瘤學、免疫學和傳染病領域開發新型治療藥物。公司總部位於倫敦，在馬薩諸塞州劍橋市設有研發機構，致力於推進小分子抑制劑和單克隆抗體候選藥物的研發，旨在調節免疫通路和靶向腫瘤生長。</p>
</div><p>The company's lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.</p>
<div class="lb-trans"><p>該公司的主要小分子項目 milciclib 是一種口服細胞週期依賴性激酶抑制劑，目前正在進行針對肝細胞癌和某些神經內分泌腫瘤的二期臨牀試驗。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Tiziana Life Sciences</li>
<li>Have $500? Invest in Elon’s AI Masterplan</li>
<li>Your Bank Account Is No Longer Safe</li>
<li>Silver paying 20% dividend. Plus 68% share gains</li>
<li>The Fed Just Got Kneecapped — Here’s What Happens Next</li>
<li>This $15 Stock Could Go Down as the #1 Stock of 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Tiziana Life Sciences</li>
<li>有 500 美元？投資於埃隆的人工智能大師計劃</li>
<li>你的銀行賬户不再安全</li>
<li>白銀支付 20% 的股息，外加 68% 的股價上漲</li>
<li>美聯儲剛剛遭遇重創——接下來會發生什麼</li>
<li>這隻 15 美元的股票可能會成為 2026 年的第一隻股票</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送郵件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Tiziana Life Sciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元於 Tiziana Life Sciences 嗎？</h2>
</div><p>Before you consider Tiziana Life Sciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Tiziana Life Sciences 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tiziana Life Sciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 Tiziana Life Sciences 並不在名單上。</p>
</div><p>While Tiziana Life Sciences currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Tiziana Life Sciences 目前在分析師中被評為賣出，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Tiziana Life Sciences（NASDAQ:TLSA）股價上漲 0.7% - 事情經過如下